Search Browse Earnings

Nurix Therapeutics, Inc. — SlamSEC

Nurix Therapeutics, Inc.

Nasdaq:NRIX

Pharmaceutical Preparations·BRISBANE, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$77.0M

+99.3% YoY

FY 2025

Adj. EBITDA

-$147.5M

-191.6% margin

FY 2025

Net Income

-$143.9M

-187.0% margin

FY 2025

EPS (Diluted)

-$2.65

FY 2025

Stock Price

$15.10

-0.7%

2026-03-06

52W Range

$8.18 – $22.50

P/E Ratio

-5.7x

Market Cap

$1.6B

Cash

$54.6M

FY 2025

Total Debt

—

Net Cash

$54.6M

FY 2025

Enterprise Value

$1.5B

Debt / EBITDA

0.4x

FY 2025

EV / EBITDA

-10.2x

Employees

—

CEO

Sands Arthur T

CFO

Van Houte Hans